A key factor to successful gene therapy is efforts to monitor the fate of gene-corrected cells. Lentivirus and AAV vectors can efficiently introduce new genetic material into human cells; however, risks exist for genotoxicity and malignant transformation. This panel of experts will discuss state-of-the-art technologies and assays for integration site profiling, clonality, and oncogenesis.
Speakers
-
Moderators: Jessica Lynch, PhD - Johnson and Johnson, and Andrew Wilber, PhD - Southern Illinois University School of Medicine
-
Frederic Bushman, PhD - Perelman School of Medicine at the University of Pennsylvania
Genomic analysis of retroviral and AAV gene therapy vectors and consequences for the human genome
-
Markus Grompe, MD - Oregon Health and Science University
Preclinical evaluation of AAV for safety and efficacy in treatment of metabolic disorders
-
Silvana Libertini, PhD - Novartis
Safety of cell therapy products - methods to assess tumorigenicity
Watch on demand
More ASGCT Insights
Register for more sessions during ASGCT Insights Week, Oct. 16-20. Members and registrants can watch on demand!